Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study

Cyrille Hulin, Aurore Perrot, Margaret Macro, Anne Vekhoff, Xavier Leleu, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah, Régis Kaphan, Charles Zarnitsky, Daniel Re, Laure Christophe, Olivier Fitoussi, Nathalie Texier, Raphael Germain, Marion Willaime, Olivier Decaux

Blood (2022) 140 (Supplement 1): 7133–7135.

https://doi.org/10.1182/blood-2022-159424

Published: 2022

Journal Articles

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2021-150498

Published: 2021

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort

Blood (2021) 138 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2021-149433

Published: 2021

Journal Articles

RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?

Blood (2021) 138 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2021-149480

Published: 2021

Journal Articles

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Rémy Duléry, MD, Laure Lebras, MD, Sylvain Choquet, MD, Roberta Di Blasi, Ahmad Kanj AL Jijakli, Laurence Heuberger, Eolia Brissot, MD PhD, Giorgia Battipaglia, MD, Florent Malard, MD PhD, Clemence Mediavilla, MD, Anne Vekhoff, MD, Paul Coppo, MD PhD, Tounes Ledraa, MD, Zora Marjanovic, Elise Corre, MD, Simona Lapusan, MD, Malek Aoudjhane, MD, Ramdane Belhocine, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 786.

https://doi.org/10.1182/blood-2019-130651

Published: 2019

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Pierre-Edouard Debureaux, Myriam Labopin, MD PhD, Simona Lapusan, MD, Francoise Isnard, PhD, Rosa Adaeva, Agnès Bonnin, Pierre Hirsch, MDPhD, Francois Delhommeau, MD PhD, Giorgia Battipaglia, MD, Remy Duléry, MD, Federica Giannotti, MD, Florent Malard, MDPhD, Annalisa Ruggeri, MD, Anne Vekhoff, Ollivier Legrand, MD PhD, Mohamad Mohty, MD PhD, Eolia Brissot, MDPhD

Blood (2017) 130 (Supplement 1): 4603.

https://doi.org/10.1182/blood.V130.Suppl_1.4603.4603

Published: 2017

Journal Articles

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Mohamad Mohty, MD PhD, Florent Malard, MDPhD, Evelyne D'Incan, MD, Xavier Thomas, MD, Christian Recher, MD PhD, Anne-Sophie Michallet, MD PhD, Pierre Peterlin, MD, Anne Vekhoff, Norbert Vey, Emilie Plantamura, Philippe Lehert, Joel Doré, Ollivier Legrand, MD PhD

Blood (2017) 130 (Supplement 1): 2624.

https://doi.org/10.1182/blood.V130.Suppl_1.2624.2624

Published: 2017

Journal Articles

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Blood (2016) 128 (22): 4624.

https://doi.org/10.1182/blood.V128.22.4624.4624

Published: 2016

Journal Articles

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Remy Dulery, MD, Anthony Dohan, MD, Maxime Barat, Mor Seny Gueye, Catherine Phan, MD, Zora Marjanovic, MD, Malek Aoudjhane, MD, Elise Corre, MD, Marie-Paule Lemonnier, MD, Anne Vekhoff, MD, Laurent Garderet, MD PhD, Ollivier Legrand, MD PhD, Paul Coppo, MD PhD, Philippe Soyer, MD PhD, Caroline Reinhold, MD, Lionel Arrivé, MD PhD, Benoit Gallix, MD PhD, Mohamad Mohty, MD PhD

Blood (2016) 128 (22): 1832.

https://doi.org/10.1182/blood.V128.22.1832.1832

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Remy Dulery, MD, Zora Marjanovic, MD, Malek Aoudjane, MD, Elise Corre, MD, Marie-Paule Lemonnier, MD, Anne Vekhoff, MD, Paul Coppo, MD PhD, Mohamad Mohty, MD PhD

Blood (2015) 126 (23): 5506.

https://doi.org/10.1182/blood.V126.23.5506.5506

Published: 2015

Journal Articles

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Pierre Hirsch, MD, Myriam Labopin, Christophe Marzac, MD, Anne-Claire Mamez, MD, Ruoping Tang, Françoise Isnard, MD, Simona Lapusan, Anne Vekhoff, MD, Norbert C Gorin, MD, Jean-Pierre Marie, Mohamad Mohty, Ollivier Legrand, MD PhD

Blood (2014) 124 (21): 1033.

https://doi.org/10.1182/blood.V124.21.1033.1033

Published: 2014

Journal Articles

Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)

Francois Guilhot, Francoise Rigal-Huguet, MD, Joelle Guilhot, PhD, Agnès Guerci-Bresler, MD, Franck E. Nicolini, MD PhD, Frédéric Maloisel, Delphine Rea, MD PhD, Valerie Coiteux, MD, Martine Gardembas, MD, Anne Vekhoff, MD, Eric Jourdan, MD PhD, Laurence Legros, MD PhD, Martine Escoffre-Barbe, MD, Philippe Rousselot, MD, Claude Preudhomme, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2014) 124 (21): 1793.

https://doi.org/10.1182/blood.V124.21.1793.1793

Published: 2014

Journal Articles

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Mathieu Leclerc, MD, Felipe Suarez, MD, PhD, Marie-Pierre Noël, MD, Anne Vekhoff, MD, Xavier Troussard, MD, Jean-François Claisse, MD, Catherine Thieblemont, MD, PhD, Frédéric Maloisel, MD, PhD, Yves Beguin, MD, PhD, Jérôme Tamburini, MD, PhD, Coralie Barbe, MD, Alain Delmer, MD

Blood (2013) 122 (21): 5308.

https://doi.org/10.1182/blood.V122.21.5308.5308

Published: 2013

Journal Articles

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Veronique Leblond, MD, Sylvie Chevret, marie Sarah Dilhuydy, Xavier Leleu, MD, PhD, Carole Soussain, MD, Stéphane Leprêtre, MD, Brigitte Dreyfus, Caroline Dartigeas, Beatrice Mahe, Bruno Anglaret, MD, Brigitte Pegourie, MD, Caroline Besson, MD, PhD, Therese Aurran, Anne Vekhoff, MD, Olivier Tournilhac, MD, PhD, Anne Banos, MD, Herve Oya, Julie Lejeune, Pierre Morel

Blood (2013) 122 (21): 4359.

https://doi.org/10.1182/blood.V122.21.4359.4359

Published: 2013

Journal Articles

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD, Claude Preudhomme, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Franck E. Nicolini, MD, PhD, Francoise Rigal-Huget, MD, Hyacinthe Johnson-Ansah, MD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, Eric Jourdan, MD, Laurence Legros, MD, PhD, Francois Guilhot

Blood (2012) 120 (21): 168.

https://doi.org/10.1182/blood.V120.21.168.168

Published: 2012

Journal Articles

The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies

Anne Bergeron, Raphaël Porcher, Annie Sulahian, Cédric de Bazelaire, Karine Chagnon, Emmanuel Raffoux, Anne Vekhoff, Muriel Cornet, Françoise Isnard, Benoit Brethon, Claire Lacroix, Jean Louis Poirot, Claire Bouges, Francis Derouin, Abdellatif Tazi, Patricia Ribaud

Blood (2012) 119 (8): 1831–1837.

https://doi.org/10.1182/blood-2011-04-351601

Published: 2012

Journal Articles

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Hyacinthe Johnson-Ansah, MD, Joelle Guilhot, Philippe Rousselot, MD, PhD, Rea Delphine, MD, PhD, Francoise Rigal-Huguet, MD, Franck E. Nicolini, MD, PhD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, PhD, Michele Schoenwald, MD, Eric Jourdan, Laurence Legros, Valérie Coiteux, MD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, Francois Guilhot

Blood (2011) 118 (21): 456.

https://doi.org/10.1182/blood.V118.21.456.456

Published: 2011

NARROW

Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort

RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only